Works in Clinical Lymphoma, Myeloma & Leukemia, 2019, Vol 19


Results: 1240
    1

    Editorial Board.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, n. 12, p. A4, doi. 10.1016/S2152-2650(19)32115-9
    Publication type:
    Article
    2

    Table of Contents.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, n. 12, p. A11, doi. 10.1016/S2152-2650(19)32116-0
    Publication type:
    Article
    3
    4
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16

    Table of Contents.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, n. 11, p. A12,A19, doi. 10.1016/S2152-2650(19)32056-7
    Publication type:
    Article
    17

    Editorial Board.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, n. 11, p. A4, doi. 10.1016/S2152-2650(19)32055-5
    Publication type:
    Article
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28

    Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia.

    Published in:
    2019
    By:
    • Kipps, Thomas J.;
    • Fraser, Graeme;
    • Coutre, Steven E.;
    • Brown, Jennifer R.;
    • Barrientos, Jacqueline C.;
    • Barr, Paul M.;
    • Byrd, John C.;
    • O'Brien, Susan M.;
    • Dilhuydy, Marie-Sarah;
    • Hillmen, Peter;
    • Jaeger, Ulrich;
    • Moreno, Carol;
    • Cramer, Paula;
    • Stilgenbauer, Stephan;
    • Chanan-Khan, Asher A.;
    • Mahler, Michelle;
    • Salman, Mariya;
    • Eckert, Karl;
    • Solman, Isabelle G.;
    • Balasubramanian, Sriram
    Publication type:
    journal article
    29
    30
    31
    32

    Author Index.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. 1, doi. 10.1016/j.clml.2019.07.390
    Publication type:
    Article
    33

    Table of Contents.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. A2, doi. 10.1016/s2152-2650(19)31281-9
    Publication type:
    Article
    34

    Welcome Message.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. A1, doi. 10.1016/S2152-2650(19)32020-8
    Publication type:
    Article
    35
    36
    37
    38
    39
    40
    41
    42

    Standardization of High Sensitivity Minimal Residual Disease Monitoring in Multiple Myeloma: An Experience in Tertiary Cancer Centre.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e357, doi. 10.1016/j.clml.2019.09.590
    By:
    • Subramanian, P.G.;
    • Chatterjee, Gaurav;
    • Ghogale, Sitaram;
    • Gokarn, Anant;
    • Gudapati, Prathyusha;
    • Deshpande, Nilesh;
    • Yajamanam, Badrinath;
    • Patkar, Nikhil;
    • Amare, Prathibha;
    • Inamdar, Nitin;
    • Punatar, Sachin;
    • Bagal, Bhausaheb;
    • Jain, Hasmukh;
    • Sengar, Manju;
    • Khattry, Navin;
    • Gujral, Sumeet;
    • Tembhare, Prashant
    Publication type:
    Article
    43
    44
    45
    46
    47

    Role of lncRNAs as prognostic factor and potential therapeutic target in Multiple Myeloma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e354, doi. 10.1016/j.clml.2019.09.585
    By:
    • Carrasco-Leon, Arantxa;
    • Ezponda, Teresa;
    • Meydan, Cem;
    • Valcárcel, Luis Vítores;
    • Ordoñez, Raquel;
    • Kulis, Marta;
    • Garate, Leire;
    • Miranda, Estíbaliz;
    • Segura, Víctor;
    • Guruceaga, Elisabeth;
    • Vilas-Zornoza, Amaia;
    • Alignani, Diego;
    • Castro-Labrador, Laura;
    • Pascual, Marién;
    • Amundarain, Ane;
    • El Omri, Halima;
    • Taba, Ruba Y.;
    • Calasanz, Maria-Jose;
    • Planes, Francisco;
    • Paiva, Bruno
    Publication type:
    Article
    48
    49

    Daratumumab + Lenalidomide, Bortezomib & Dexamethasone Improves Depth of Response in Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e353, doi. 10.1016/j.clml.2019.09.583
    By:
    • Voorhees, Peter;
    • Kaufman, Jonathan L.;
    • Laubach, Jacob;
    • Sborov, Douglas;
    • Reeves, Brandi;
    • Rodriguez, Cesar;
    • Chari, Ajai;
    • Silbermann, Rebecca;
    • Costa, Luciano;
    • Anderson, Larry;
    • Nathwani, Nitya;
    • Shah, Nina;
    • Efebera, Yvonne;
    • Costello, Caitlin;
    • Jakubowiak, Andrzej;
    • Wildes, Tanya;
    • Orlowski, Robert Z.;
    • Shain, Kenneth H.;
    • Cowan, Andrew;
    • Murphy, Sean
    Publication type:
    Article
    50

    Activity of Melflufen in RR MM Patients with Extramedullary Disease in the Phase 2 HORIZON Study (OP-106): Promising Results in a High-Risk Population.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e352, doi. 10.1016/j.clml.2019.09.582
    By:
    • Richardson, Paul G.;
    • Mateos, Maria-Victoria;
    • Rodríguez-Otero, Paula;
    • Norkin, Maxim;
    • Larocca, Alessandra;
    • Hassoun, Hani;
    • Alegre, Adrian;
    • Paner, Agne;
    • Leleu, Xavier;
    • Maisel, Christopher;
    • Mazumder, Amitabha;
    • Harmenberg, Johan;
    • Byrne, Catriona;
    • Zubair, Hanan;
    • Thuresson, Sara;
    • Blade, Joan
    Publication type:
    Article